Home › Companies › BEAM THERAPEUTICS INC. › 2024-2025

BEAM THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BEAM THERAPEUTICS INC.’s Form 8-K, filed 2025-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Ballot items
277Asset managers
1,414Fund votes
2025-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BEAM THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BEAM THERAPEUTICS INC.

These tallies are BEAM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BEAM THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mark Fishman, M.D.	61,949,019	10,285,110	63,755	--	12,201,172	Majority: yes
Elect Director: Carole Ho, M.D.	71,720,651	548,021	29,212	--	12,201,172	Majority: yes
Elect Director: Kathleen Walsh	71,888,413	379,636	29,835	--	12,201,172	Majority: yes
Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 was ratified, based on the following votes:	84,281,031	154,426	63,599	--	--	Majority: yes
Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:	71,701,062	562,871	33,951	--	12,201,172	Majority: yes

Source: BEAM THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-06 — read the filing on EDGAR.

How asset managers voted at the BEAM THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 277 asset managers that disclosed a BEAM THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-04.

Combines 9 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 71,701,062AGAINST: 562,871

BEAM THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”): 71,701,062 for, 562,871 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 71% for, 0.6% against (72% of the company cast a for/against vote).

The 271 asset managers below cast 99.5% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99.1%

FOR: 99.2%AGAINST: 0.4%ABSTAIN: 0.4%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Fidelity	9,605,540	0	0	For
Vanguard	8,976,139	0	0	For
FARALLON CAPITAL MANAGEMENT LLC	8,056,102	0	0	For
ARK ETF Trust	7,995,179	0	0	For
BlackRock	5,694,302	0	0	For
T. Rowe Price	5,105,045	0	0	For
ARCH Venture Management, LLC	4,540,132	0	0	For
Nikko Asset Management Co., Ltd.	4,433,768	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,954,882	0	0	For
Temasek Holdings (Private) Ltd	1,812,972	0	0	For
State Street	1,727,886	7,501	0	For
Charles Schwab	1,566,997	0	0	For
Redmile Group, LLC	1,527,342	0	0	For
Impresa Management LLC	1,139,443	0	0	For
JPMorgan	830,247	0	0	For
Woodline Partners LP	760,611	0	0	For
Avidity Partners Management LP	559,517	0	0	For
EcoR1 Capital, LLC	526,685	0	0	For
Northern Trust	489,005	0	0	For
Janus Henderson	433,883	0	0	For
RTW INVESTMENTS, LP	424,248	0	0	For
Kynam Capital Management, LP	0	0	291,041	Abstain
Equitable	271,679	0	0	For
Citadel	226,406	0	0	For
ARK Investment Management LLC	209,642	0	0	For

Showing the 25 largest of 271 asset managers. See all 271 in the interactive database.

2. Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Carole Ho, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-04.

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 71,720,651AGAINST: 548,021

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carole Ho, M.D.”): 71,720,651 for, 548,021 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 71% for, 0.6% against (72% of the company cast a for/against vote).

The 64 asset managers below cast 99.5% of the shares they voted on this item FOR (29,369,747 for, 126,726 against).

FOR 99.5%

FOR: 29,369,747 (99.6%)AGAINST: 126,726 (0.4%)ABSTAIN: 5,512 (0.0%)

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,828	0	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	For
TIAA	196,720	0	0	For
State Street	181,385	0	0	For
JPMorgan	149,674	0	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	132,736	0	0	For
Pacific Life	130,302	0	0	For
Lincoln Financial	99,381	3,184	0	For
American Century	99,408	0	0	For
AIG/SunAmerica	74,839	0	0	For
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	60,077	0	0	For
Brighthouse	50,497	0	5,512	For
Transamerica	55,500	0	0	For
MFS	55,346	0	0	For
Northern Trust	54,062	0	0	For
WisdomTree	51,544	0	0	For
Bridge Builder Trust	50,557	0	0	For
ProShares	45,776	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

3. Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Kathleen Walsh

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-04.

Combines 3 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 71,888,413AGAINST: 379,636

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathleen Walsh”): 71,888,413 for, 379,636 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 71% for, 0.4% against (72% of the company cast a for/against vote).

The 64 asset managers below cast 99.5% of the shares they voted on this item FOR (29,369,747 for, 126,726 against).

FOR 99.5%

FOR: 29,369,747 (99.6%)AGAINST: 126,726 (0.4%)ABSTAIN: 5,512 (0.0%)

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,828	0	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	For
TIAA	196,720	0	0	For
State Street	181,385	0	0	For
JPMorgan	149,674	0	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	132,736	0	0	For
Pacific Life	130,302	0	0	For
Lincoln Financial	99,381	3,184	0	For
American Century	99,408	0	0	For
AIG/SunAmerica	74,839	0	0	For
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	60,077	0	0	For
Brighthouse	50,497	0	5,512	For
Transamerica	55,500	0	0	For
MFS	55,346	0	0	For
Northern Trust	54,062	0	0	For
WisdomTree	51,544	0	0	For
Bridge Builder Trust	50,557	0	0	For
ProShares	45,776	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

4. Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Mark Fishman, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-04.

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST 14%

FOR: 61,949,019AGAINST: 10,285,110

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Fishman, M.D.”): 61,949,019 for, 10,285,110 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 62% for, 10% against (72% of the company cast a for/against vote).

The 64 asset managers below cast 97% of the shares they voted on this item FOR (28,680,487 for, 815,986 against).

FOR 97%

FOR: 28,680,487 (97.2%)AGAINST: 815,986 (2.8%)ABSTAIN: 5,512 (0.0%)

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,066	762	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	For
TIAA	196,720	0	0	For
State Street	181,213	172	0	For
JPMorgan	149,674	0	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	0	132,736	0	Against
Pacific Life	130,302	0	0	For
Lincoln Financial	86,221	16,344	0	For
American Century	0	99,408	0	Against
AIG/SunAmerica	0	74,839	0	Against
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	27,958	32,119	0	Against
Brighthouse	44,518	5,979	5,512	For
Transamerica	55,500	0	0	For
MFS	0	55,346	0	Against
Northern Trust	0	54,062	0	Against
WisdomTree	0	51,544	0	Against
Bridge Builder Trust	42,882	7,675	0	For
ProShares	0	45,776	0	Against

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

5. RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-04.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 84,281,031AGAINST: 154,426

BEAM THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 was ratified, based on the following votes:”): 84,281,031 for, 154,426 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 84% for, 0.2% against (84% of the company cast a for/against vote).

The 64 asset managers below cast 99.9% of the shares they voted on this item FOR (29,495,783 for, 690 against).

FOR 99.9%

FOR: 29,495,783 (100.0%)AGAINST: 690 (0.0%)ABSTAIN: 5,512 (0.0%)

Largest asset managers voting on “RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR F” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,716,828	0	For
ARK ETF Trust	7,995,179	0	For
Fidelity	4,653,310	0	For
BlackRock	2,784,446	0	For
T. Rowe Price	2,272,505	0	For
Charles Schwab	783,402	0	For
Equitable	271,679	0	For
TIAA	196,720	0	For
State Street	181,385	0	For
JPMorgan	149,674	0	For
Global X	141,913	0	For
JANUS INVESTMENT FUND	132,736	0	For
Pacific Life	130,302	0	For
Lincoln Financial	102,565	0	For
American Century	99,408	0	For
AIG/SunAmerica	74,839	0	For
Yiheng Capital Management, L.P.	69,058	0	For
John Hancock	60,077	0	For
Brighthouse	50,497	5,512	For
Transamerica	55,500	0	For
MFS	55,346	0	For
Northern Trust	54,062	0	For
WisdomTree	51,544	0	For
Bridge Builder Trust	50,557	0	For
ProShares	45,776	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

6. Approve, on an advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-05 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 56,501,513AGAINST: 1,295,311

BEAM THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”): 56,501,513 for, 1,295,311 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,557,094 outstanding shares: 56% for, 1% against (57% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (98 for, 0 against).

FOR 100%

FOR: 98 (100.0%)

Largest asset managers voting on “Approve, on an advisory basis, the compensation of our named executive officers.” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	98	0	0	0	For
Echo45 Advisors LLC	0	0	0	0	--

Largest BEAM THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of BEAM THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 100,557,094 shares outstanding at the time of that meeting.

Top BEAM THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	9.55%
2	Vanguard	8.93%
3	FARALLON CAPITAL MANAGEMENT LLC	8.01%
4	ARK ETF Trust	7.95%
5	BlackRock	5.66%
6	T. Rowe Price	5.08%
7	ARCH Venture Management, LLC	4.51%
8	Nikko Asset Management Co., Ltd.	4.41%
9	GEODE CAPITAL MANAGEMENT, LLC	1.94%
10	Temasek Holdings (Private) Ltd	1.80%

Reported BEAM THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BEAM THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	12.40%	13G
FMR LLC and affiliates	9.99%	DEF14A
Farallon Partners, L.L.C.	9.75%	13G
Farallon Capital Partners and affiliates	9.59%	DEF14A
Vanguard Group	8.82%	13F
BlackRock	8.06%	13F
FMR (Fidelity)	7.88%	13F
State Street	3.42%	13F
T. Rowe Price	3.01%	13F
Citadel Advisors	2.69%	13F

Percentages above are of 100,557,094 shares outstanding, as reported by BEAM THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BEAM THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BEAM THERAPEUTICS INC.'s shareholder meeting held 2025-06-04, in the 2024-2025 proxy season, 277 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,414 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — FOR was 99.2% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BEAM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-06.

BEAM THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.